Quantcast

Latest Multiple drug resistance Stories

d9cb6efcabb4e36f019ac62b281faa60
2009-11-10 11:08:10

Using antibiotics to excess is causing extensive resistance in parts of Europe and may stop fundamental medical care like hip replacements, intensive care for premature children and cancer treatment, health experts announced. Dominique Monnet of the European Centre for Disease Prevention and Control's (ECDC) scientific counsel unit found that the "whole span of modern medicine" is being faced with danger because viruses are become defiant to antibiotic treatment, making the drugs...

2009-10-28 23:01:00

CHAPEL HILL, N.C., Oct. 29 /PRNewswire/ -- Cempra Pharmaceuticals today announced a presentation on its novel fluoroketolide antibiotic, CEM-101, at the Infectious Diseases Society of America, 47th Annual Meeting, October 29 to November 1, 2009, in Philadelphia. Susceptibility of CEM-101 and more than 25 other antibiotics was tested against 1,737 multidrug-resistant S. pneumoniae strains collected in 2008 from medical centers in the U.S., Europe and Latin America. CEM-101 demonstrated...

2009-10-22 06:00:00

EMERYVILLE, Calif., Oct. 22 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE-Amex: NBY) http://www.novabaypharma.com, a clinical stage company developing non-antibiotic antimicrobial compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, today announced that Thomas Paulson, Chief Financial Officer, will deliver a corporate presentation at the Bio Investor Forum 2009 being held at The Palace Hotel in San Francisco. Mr. Paulson's...

2009-10-14 11:03:00

Using small molecules (purine analogs) scientists managed to reverse multidrug resistance in lung cancer, a common obstacle to successful cancer chemotherapy. BELGRADE, Serbia, Oct. 14 /PRNewswire-FirstCall/ - HTDS www.htdsmedical.com (HTDS) - The issuer's Serbia based operating subsidiary Slavica BioChem www.slavicabiochem.com brings attention to its Mindup Bioresearch cancer project working on molecular origins of lung cancer: prospects for personalized prevention and...

2009-10-08 06:00:00

BOSTON, Oct. 8 /PRNewswire-FirstCall/ -- Paratek Pharmaceuticals, Inc. announced today that it has entered into an exclusive worldwide collaborative development, manufacturing and commercialization license agreement with Novartis for Paratek's lead broad-spectrum antibiotic, PTK 0796, a first-in-class aminomethylcycline (AMC) in Phase 3 clinical trials. PTK 0796 is the most advanced once-daily, oral and IV antibiotic with a spectrum that is broad enough for single-agent treatment of life...

2009-10-07 11:22:00

NEW HAVEN, Conn., Oct. 7 /PRNewswire/ -- Rib-X Pharmaceuticals, Inc., a company focused on the discovery, development and commercialization of novel drugs for the treatment of multi-antibiotic resistant infections, today announced that Rib-X Co-Founder and Chair of the Scientific Advisory Board, Sterling Professor of Molecular Biophysics and Biochemistry at Yale University and a Howard Hughes Medical Institute Investigator, Thomas A. Steitz, Ph.D., has been awarded the Nobel Prize in...

2009-09-28 15:05:32

Canadian researchers say they've identified a chemical compound that targets drug-resistant bacteria in a different way from existing antibiotics. McMaster University scientists say their discovery is an ideal starting point to develop new interventions for resistant infections. Despite the need for new treatment options, the scientists note there have been only two new classes of antibiotics developed during the last 40 years. Professor Eric Brown and colleagues from the Michael DeGroote...

2009-09-24 09:00:00

EMERYVILLE, Calif., Sept. 24 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE-AMEX: NBY) http://www.novabaypharma.com, a clinical stage company developing non-antibiotic antimicrobial compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today that Ron Najafi, Ph.D., Chairman and Chief Executive Officer, will present at the Maxim Group Growth Conference at 10 a.m. (ET), Tuesday, Sept. 29, 2009 at the Grand Hyatt Hotel in...

2009-09-14 13:15:00

EMERYVILLE, Calif., Sept. 14 /PRNewswire-FirstCall/ -- NovaBay(R) Pharmaceuticals, Inc. (NYSE-AMEX: NBY) (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, presented in two poster sessions today at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco. These two separate laboratory studies of its...

2009-09-10 05:30:00

EMERYVILLE, Calif., Sept. 10 /PRNewswire-FirstCall/ -- NovaBay(R) Pharmaceuticals, Inc. (NYSE-Amex: NBY), (http://www.novabaypharma.com), a clinical stage company developing novel anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral and fungal infections, announced today the start of a Phase 2a proof-of-concept study of its lead Aganocide(R) compound NVC-422 in impetigo. NovaBay's partner in the impetigo trial is Galderma, S.A. the world's leading...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related